wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q53402902-30C72017-A1F3-40C7-9248-4B6A437F2C77
Q53402902-30C72017-A1F3-40C7-9248-4B6A437F2C77
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53402902-30C72017-A1F3-40C7-9248-4B6A437F2C77
Adverse kidney effects of epidermal growth factor receptor inhibitors.
P2860
Q53402902-30C72017-A1F3-40C7-9248-4B6A437F2C77
BestRank
Statement
http://www.wikidata.org/entity/statement/Q53402902-30C72017-A1F3-40C7-9248-4B6A437F2C77
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
0229a7623d877cceddb64fae84968b9e6f7e1f44
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.